EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

STING signaling opposes AXL to regulate interferon responses in dedifferentiated human melanoma

Carl A Shirley, Michael B Wolfe, Karla B Anaya-Aldrete, Minakshi Nihal, Gagan Chhabra, Sean J McIlwain, Julia M Krien, Mary A Ndiaye, Nihal Ahmad

Frontiers in Oncology · 05.11.2026 · 16

DOI: 10.3389/fonc.2026.1946947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 05.11.2026. Verfasst von Carl A Shirley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Wisconsin, Madison, WI, United States. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cancer cells can evade interferon (IFN) signaling pressures by suppressing intrinsic innate immune signaling pathways or dedifferentiating, giving rise to immunotherapy-resistant cell states. Therapeutic strategies specifically tailored to account for and eliminate such states remain limited.

Methods

Here, we genetically reintroduced stimulator of interferon genes (STING) in dedifferentiated STING-deficient melanoma cells, used AXL receptor tyrosine kinase (AXL) small-molecule inhibition, and analyzed publicly available single-cell RNA-sequencing (scRNA-seq) datasets to examine connections between dedifferentiation and interferon responses in human melanoma.

Results

We found that STING reintroduction induced type I IFN signaling, increased expression of antigen-presentation genes, and enhanced sensitivity to exogenous type II IFN. STING signaling silenced expression of AXL, a key marker of melanoma dedifferentiation. AXL small-molecule inhibition partially phenocopied STING reintroduction, potentiating antigen-presentation gene expression and enhancing type II IFN sensitivity in dedifferentiated human melanoma cells. Consistently, analysis of publicly available human melanoma scRNA-Seq data revealed tumor cells with concomitant STING loss and AXL gain are positively enriched for melanocyte stem-cell-like signatures, while negatively enriched for interferon and immune activation signatures.

Discussion

Together, through manipulation of human melanoma cell lines and analysis of single-cell states, our results support opposing roles for STING and AXL in the regulation of antigen-presenting genes and interferon sensitivity and more broadly implicate changes to interferon sensitivity in the dedifferentiation process.

Schlagwörter

Stichwörter der Autor:innen

Axl receptor tyrosine kinase (Axl)immune checkpoint blockade (ICB)interferon (IFN)melanomastimulator of interferon genes (STING)

Autor:innen und Institutionen

  • Department of Dermatology, University of Wisconsin, Madison, WI, United States.
  • Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States.
  • Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, United States.
  • William S. Middleton Memorial Veterans Hospital, Madison, WI, United States.

Zitieren

APA

Shirley, C. A., Wolfe, M. B., Anaya-Aldrete, K. B., Nihal, M., Chhabra, G., McIlwain, S. J., Krien, J. M., Ndiaye, M. A., & Ahmad, N. (2026). STING signaling opposes AXL to regulate interferon responses in dedifferentiated human melanoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1946947

Vancouver

Shirley CA, Wolfe MB, Anaya-Aldrete KB, Nihal M, Chhabra G, McIlwain SJ, et al. STING signaling opposes AXL to regulate interferon responses in dedifferentiated human melanoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1946947

BibTeX
@article{Shirley2026,
  author = {Shirley, Carl A and Wolfe, Michael B and Anaya-Aldrete, Karla B and Nihal, Minakshi and Chhabra, Gagan and McIlwain, Sean J and Krien, Julia M and Ndiaye, Mary A and Ahmad, Nihal},
  title = {STING signaling opposes AXL to regulate interferon responses in dedifferentiated human melanoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1946947}
}
Kostenlos starten →